Literature DB >> 2658749

Management of prolactinomas.

M E Molitch1.   

Abstract

Prolactinomas are the most common of the hormone-secreting pituitary tumors and must be distinguished from nonsecreting tumors causing hyperprolactinemia by hypothalamic or stalk dysfunction. For both micro- and macroadenomas, dopamine agonists appear to be the treatment of choice, transsphenoidal surgery being reserved for nonresponders. For women desiring pregnancy, dopamine agonists are safe when there is a microadenoma or an intrasellar macroadenoma. However, in women with large macroadenomas desiring pregnancy, limited transsphenoidal decompression followed by bromocriptine appears to be the safest mode of treatment.

Entities:  

Mesh:

Year:  1989        PMID: 2658749     DOI: 10.1146/annurev.me.40.020189.001301

Source DB:  PubMed          Journal:  Annu Rev Med        ISSN: 0066-4219            Impact factor:   13.739


  5 in total

1.  Effect of dopamine agonist medication on prolactin producing pituitary adenomas. A morphological study including immunocytochemistry, electron microscopy and in situ hybridization.

Authors:  K Kovacs; L Stefaneanu; E Horvath; R V Lloyd; I Lancranjan; M Buchfelder; R Fahlbusch
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1991

Review 2.  Diagnosis and management of pituitary tumours.

Authors:  A Levy; S L Lightman
Journal:  BMJ       Date:  1994-04-23

3.  Cabergoline as a first-line treatment in newly diagnosed macroprolactinomas.

Authors:  N Pontikides; G E Krassas; E Nikopoulou; T Kaltsas
Journal:  Pituitary       Date:  2000-05       Impact factor: 4.107

Review 4.  A practical guide to the diagnosis and management of amenorrhoea.

Authors:  P G Crosignani; W Vegetti
Journal:  Drugs       Date:  1996-11       Impact factor: 9.546

5.  A cross-over study with the two novel dopaminergic drugs cabergoline and quinagolide in hyperprolactinemic patients.

Authors:  M Giusti; E Porcella; A Carraro; M Cuttica; S Valenti; G Giordano
Journal:  J Endocrinol Invest       Date:  1994-01       Impact factor: 4.256

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.